MARLBOROUGH, Mass., May 10, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the schedule of key data
"This year's EuroPCR congress will provide us the opportunity to share the performance of our LOTUS Valve platform in the REPRISE III trial,which is the first large, global, randomized head-to-head trial of two contemporary TAVI valves, as well as findings from the RESPOND and RESPOND Extension studies," said Ian Meredith, M.D., executive vice president and global chief medical officer, Boston Scientific. "These data, along with findings from the European registry for the WATCHMAN device, further demonstrate the value our minimally-invasive structural heart therapies bring to physicians in their pursuit of delivering the highest quality care to their patients."
SCHEDULE OF PRESENTATIONS OF INTEREST (listed chronologically)
Tuesday, May 16
Wednesday, May 17
Thursday, May 18
All events are listed in Central European Summer Time (CEST) and take place at the Palais des Congrès. For additional details about Boston Scientific data presentations and sponsored symposia, go to www.bostonscientific.com/EuroPCR2017 or visit the Boston Scientific booth located on Level 1, Hall Passy F21.
The company will also host an investor event and webcast on Tuesday, May 16, from 16:00 to 17:00 (CEST)/ 10:00 to 11:00 AM (EDT) to discuss its interventional cardiology and structural heart portfolios. The live webcast and replay will be accessible at www.bostonscientific.com/investors with the latter becoming available approximately one hour following the completion of the event.
*The LOTUS™ valve system is currently not available for use or sale.**In the U.S., the Agent™ Paclitaxel-Coated balloon catheter is investigational and not available for sale.
About Boston ScientificBoston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
U.S. Media: Trish Backes(612) [email protected]
European Media: Chiara Ennas+44 (0) 7766 [email protected]
Investor Relations: Susie Lisa, CFA(508) 683-5565 (office)[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-schedule-of-presentations-at-europcr-2017-300454820.html
SOURCE Boston Scientific Corporation
Subscribe to our Free Newsletters!
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...
Hashimoto's thyroiditis is an autoimmune disorder of the thyroid causing hypothyroidism. Synthetic ...
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...View All